Andrew Dunn, Jaimy Lee and Ryan Cross
March 27, 2023 08:46 AM EDT
Editor's note

An­nounc­ing three ex­cit­ing jour­nal­ists who are join­ing the End­points news­room

Drew Armstrong

Executive Editor

To­day we’re an­nounc­ing three new mem­bers of our news­room here at End­points as part of our grow­ing cov­er­age plans and ever-ex­pand­ing am­bi­tion.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times